Department of Surgery, Kurume University School of Medicine, Kurume, Japan;
Department of Surgery, Kurume University School of Medicine, Kurume, Japan.
Anticancer Res. 2024 Aug;44(8):3645-3653. doi: 10.21873/anticanres.17188.
BACKGROUND/AIM: Laparoscopic anatomical liver resection (LAR) for hepatocellular carcinoma (HCC) is technically demanding. Therefore, this study aimed to compare the perioperative and long-term oncological outcomes of LAR and open anatomical liver resection (OAR) for HCC.
We retrospectively analyzed 460 consecutive patients who underwent anatomical liver resection as the initial treatment for primary HCC between January 2010 and February 2024. Patients were categorized into the LAR and OAR groups, and surgical outcomes between the groups were compared using 1:1 propensity score matching (PSM).
After PSM, the LAR and OAR groups included 100 patients each. The LAR group exhibited significantly less blood loss (80 vs. 436 ml; p<0.0001), lower transfusion rates (0% vs. 12%; p=0.0002), shorter operative time (345 vs. 398 min; p=0.0009), lower postoperative morbidity rates (6% vs. 34%; p<0.0001), and shorter postoperative hospital stay (8 vs. 15 days; p<0.0001) than the OAR group. The 1-, 3-, and 5-year overall survival rates were 97.7%, 96.2%, and 89.7%, respectively, in the LAR group and 98.0%, 92.7%, and 88.4%, respectively, in the OAR group (p=0.5874). The 1-, 3-, and 5-year recurrence-free survival rates were 93.2%, 75.7%, and 60.7%, respectively, in the LAR group and 86.0%, 64.5%, and 59.1%, respectively, in the OAR group (p=0.2314).
LAR showed improvements in perioperative complications, reduced postoperative hospital stay, and comparable recurrence-free and overall survival rates with those of OAR. Therefore, LAR for HCC is considered safe, feasible, and oncologically acceptable in selected patients.
背景/目的:腹腔镜解剖性肝切除术(LAR)治疗肝细胞癌(HCC)具有较高的技术要求。因此,本研究旨在比较 LAR 和开腹解剖性肝切除术(OAR)治疗 HCC 的围手术期和长期肿瘤学结果。
我们回顾性分析了 2010 年 1 月至 2024 年 2 月期间接受解剖性肝切除术作为原发性 HCC 初始治疗的 460 例连续患者。患者分为 LAR 和 OAR 组,并通过 1:1 倾向评分匹配(PSM)比较两组之间的手术结果。
PSM 后,LAR 和 OAR 组各包含 100 例患者。LAR 组的出血量明显减少(80 与 436ml;p<0.0001),输血率较低(0%与 12%;p=0.0002),手术时间较短(345 与 398min;p=0.0009),术后发病率较低(6%与 34%;p<0.0001),术后住院时间较短(8 与 15 天;p<0.0001)。LAR 组的 1 年、3 年和 5 年总生存率分别为 97.7%、96.2%和 89.7%,OAR 组分别为 98.0%、92.7%和 88.4%(p=0.5874)。LAR 组的 1 年、3 年和 5 年无复发生存率分别为 93.2%、75.7%和 60.7%,OAR 组分别为 86.0%、64.5%和 59.1%(p=0.2314)。
LAR 在围手术期并发症方面有改善,术后住院时间缩短,且与 OAR 相比,无复发生存率和总生存率相当。因此,对于选定的患者,LAR 治疗 HCC 是安全、可行且具有肿瘤学可接受性的。